Matinas BioPharma Investor Presentation Deck

25 Disease Activity Index Effect of Oral LNC-TNFa RNAi in a Murine DSS Acute Colitis Model Female C57BL/6 mice (n=55) 6 5 1 0 DSS 3.5% Untreated control DSS alone DSS+ oral LNC 1 DSS+ oral LNC 2 DSS+ oral Scrambled LNCS DSS + anti-TNFa Ab G1-DSS (3.5%)-Control G2-LNC1+DSS G3-LNC2+DSS G4-Scrambled LNC+DSS G5-anti-TNFa Ab+DSS G6-Control (Naive) 6 Groups KTH pre-Rx for 2 days, then qd 10 ug/dose 0.167 mg/mouse on day 0, 4 and 6 p < 0.01 Day 7-11 p < 0.05 - Day 10-14 p < 0.001 Day 7-14 - DSS alone vs. LNC2 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Day Fold change pg/ml COPYRIGHT MATINAS BIOPHARMA 151 Change in TNFa Tissue mRNA at Day 14 (5 per group) 10- 2- 1 0 30- 20- 10- 0 Naive T Naive 2024 DSS DSS LNC 1 45%↓ LNC 2 LNC 1 Serum TNFa at Day 14 T_p=0.014 37% SCR LNC 2 SCR TNFa Ab TNFa Ab MATINAS BIOPHARMA

View entire presentation